Table 3.
Comparison of hematological and electrolyte parameters between AC-treated and untreated BC patients.
| Variables (Mean ± SD) | Untreated (n=100) | Treated (n=100) | p-value |
|---|---|---|---|
| TWBC (/µL) | 8.47±1.85 | 5.26±1.52 | <0.0001 |
| NE (/µL) | 4.13±1.48 | 2.12±.81 | <0.0001 |
| LY (/µL) | 2.74±1.33 | 1.60±.88 | <0.0001 |
| MO (/µL) | 0.86±.37 | 0.82±.34 | 0.498 |
| EO (/µL) | 0.58±.40 | 0.75±.46 | 0.006 |
| BA (/µL) | 0.13±.12 | 0.14±.15 | 0.721 |
| RBC (/µL) | 4.52±.53 | 4.06±.64 | <0.0001 |
| Hgb (g/dL) | 12.49±1.29 | 11.08±.84 | <0.0001 |
| HCT (%) | 36.99±3.98 | 33.01±2.31 | <0.0001 |
| RDW (%) | 12.86±1.79 | 18.39±2.77 | <0.0001 |
| MCV (fL) | 81.96±7.86 | 80.13±8.35 | 0.113 |
| MCH (pg) | 27.91±2.65 | 27.70±3.33 | 0.630 |
| MCHC (g/dL) | 33.61±1.12 | 33.54±1.15 | 0.648 |
| PLT(/µL) | 245.68±76.16 | 373.88±147.99 | <0.0001 |
| MPV (%) | 8.23±1.14 | 7.96±1.15 | 0.092 |
| PCT (%) | 0.13±.04 | 0.22±.08 | <0.0001 |
| Na+(mmol/L) | 142.43±4.47 | 133.34±6.11 | <0.0001 |
| Ca2+(mg/dL) | 8.62±.89 | 8.75±1.01 | 0.330 |
| K+ (mmol/L) | 3.81±.50 | 5.22±.107 | <0.0001 |
TWBC, Total White Blood Cell; NE, Neutrophil; LY, Lymphocyte; MO, Monocyte; EO, Eosinophils; BA, Basophil; RBC, Red Blood Cell; Hgb, Hemoglobin; HCT, Hematocrit; RDW, Red Cell Distribution Width; MCV, Mean Cell Volume; MCH, Mean Cell Hemoglobin; MCHC, Mean Cell Hemoglobin Concentration; PLT, Platelet; MPV, Mean Platelet Volume; PCT, Plateletcrit, Na+: Sodium, Ca2+: Calcium, K+: Potassium, BC: breast cancer, AC: Adriamycin-Cytoxan. Continuous variables were expressed as mean ± standard deviation (SD) and p-value < 0.05 implies a significant difference between the two study group’s variables.